GlassScriptPhysician profile
Megan Gardner
NPI 1932577871
$1,680.63
in general payments reported to CMS, 2019-2025
17 companies · $969 in 2025
The $969 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $161 · 2024: $550 · 2025: $969.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,681.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,680.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $409.74 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $276.04 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $153.89 | 2024-2025 | |
| Pfizer INC. | $149.65 | 2024-2025 | |
| Lilly USA, LLC | $116.18 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Exact Sciences Corporation | $101.62 | 2024-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $89.43 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $77.48 | 2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $75.78 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $71.75 | 2024-2025 | Caplyta |
| Astellas Pharma US INC | $43.94 | 2025 | Veozah |
| Axsome Therapeutics, INC. | $31.01 | 2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $19.83 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $16.72 | 2024 | Opsumit, Uptravi |
| Amgen INC. | $16.16 | 2024 | Otezla, Repatha |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $16.15 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.26 | 2024 | Ofev |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Gardner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.